Skip to main content
letter
. 2023 Jul 13;108(12):3502–3505. doi: 10.3324/haematol.2023.283452

Figure 1.

Figure 1.

Profile of analyzed population. The diagram shows the distribution of analyzed patients. NDMM: newly-diagnosed multiple myeloma patients; Dara-VTd: daratumumab, bortezomib, thalidomide and dexamethasone; HD-CTX: high-dose cyclophosphamide; ASCT: autologous stem cell transplantation; PNP: peripheral neuropathy.